<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01736878</url>
  </required_header>
  <id_info>
    <org_study_id>EARL-2</org_study_id>
    <secondary_id>2011-006250-90</secondary_id>
    <nct_id>NCT01736878</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Sorafenib to Treat Advanced Medullary Thyroid Carcinoma</brief_title>
  <acronym>SUMMIT</acronym>
  <official_title>Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eanm Research Ltd</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eanm Research Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of his study is to evaluate the efficacy and safety of Sorafenib versus placebo&#xD;
      in subjects with locally advanced medullary thyroid cancer (MTC). The primary study objective&#xD;
      is to compare the Progression-free Survival (PFS) of the Sorafenib treatment group with the&#xD;
      placebo treatment group in patients with advanced MTC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Study was withdrawn due to unanticipated hassle in patient recruitment.&#xD;
  </why_stopped>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>from the date of randomisation until the date of radiological or biochemical progression or death. An average of 9 months is assumed.</time_frame>
    <description>The proportion of patients with PFS in the Sorafenib group and the Placebo group will be compared by log rank test and Kaplan-Meier plot.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TPP)</measure>
    <time_frame>from the date of randomisation until the date of confirmed radiological or biochemical progression. An average of 9 months is assumed.</time_frame>
    <description>The average TTP in the Sorafenib group and the Placebo group will be compared.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>from the date of randomisation until the date of death due to any cause. Final assessment at the end of study after approximately 36 months.</time_frame>
    <description>The proportion of surviving patients in the Sorafenib group and the Placebo group will be compared.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Medullary Thyroid Carcinoma</condition>
  <arm_group>
    <arm_group_label>Sorafenib tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral administration of Sorafenib tablets, 400 mg bid, until disease progression or unacceptable toxicity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral administration of Placebo tablets until disease progression, afterwards continuation with Sorafenib at the discretion of the investigator</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib</intervention_name>
    <arm_group_label>Placebo tablets</arm_group_label>
    <arm_group_label>Sorafenib tablets</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inpatient or outpatient ≥ 18 years of age&#xD;
&#xD;
          -  Histologically confirmed medullary thyroid carcinoma&#xD;
&#xD;
          -  Recurrent or persistent local disease and/or distant metastases&#xD;
&#xD;
          -  No more than one prior line of systemic therapy&#xD;
&#xD;
          -  Best available supportive care to control (endocrine) symptoms&#xD;
&#xD;
          -  At least one defined lesion in CT or MRI evaluable for Response Evaluation Criteria in&#xD;
             Solid Tumors (RECIST v1.1), or at least one defined lesion in CT or MRI not evaluable&#xD;
             by RECIST in combination with elevated tumour markers&#xD;
&#xD;
          -  Progression within previous 12 months&#xD;
&#xD;
          -  Hb &gt; 8g/dl, white blood cells (WBC) &gt;3.000 cells/mm³ (ANC &gt; 1.500 cells/mm³),&#xD;
             platelets &gt; 100.000 cells/mm³, bilirubin &lt; 2mg/dl, alanine aminotransferase (ALT) and&#xD;
             aspartate aminotransferase (AST) &lt; 2.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Performance status: WHO ≤ 2; Karnofsky index ≥ 50%&#xD;
&#xD;
          -  Sufficient renal function (creatinin &lt;1.5 mg/dl and creatinin clearance &gt; 30ml/min)&#xD;
&#xD;
          -  International normalized ratio (INR) and partial thromboplastin time (PTT) &lt; 1.5 x ULN&#xD;
&#xD;
          -  No acute infections&#xD;
&#xD;
          -  Staging studies (MRT or CT and Calcitonin or CEA) completed within four weeks of&#xD;
             protocol randomisation&#xD;
&#xD;
          -  Women of childbearing potential with negative serum pregnancy test&#xD;
&#xD;
          -  Women and men of childbearing potential using adequate contraception&#xD;
&#xD;
          -  Signed and dated written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unresolved toxicity (i.e. neurotoxicity) attributed to any prior therapy higher than&#xD;
             National Cancer Institute-Common Toxicity Criteria for Adverse Effects (NCI-CTCAE&#xD;
             version 4) Grade 2 (excluding cases of alopecia)&#xD;
&#xD;
          -  Patients with history of allergic or hypersensitivity reaction to study drug or&#xD;
             placebo or their excipients&#xD;
&#xD;
          -  Current participation in another investigational trial&#xD;
&#xD;
          -  Patients with significant cardiovascular disease&#xD;
&#xD;
          -  Cardiac ventricular arrhythmias requiring anti-arrhythmic therapy other than&#xD;
             beta-blockers or digoxin&#xD;
&#xD;
          -  Congenital long corrected QT interval (QTc) syndrome, history of drug induced QTc&#xD;
             prolongation, or QTc interval unmeasurable or more than 450 ms&#xD;
&#xD;
          -  Abnormal serum electrolytes such as potassium, magnesium and calcium&#xD;
&#xD;
          -  Uncontrolled hypertension, despite optimal management&#xD;
&#xD;
          -  Major surgery, open biopsy, or significant traumatic injury within 30 days prior to&#xD;
             randomization&#xD;
&#xD;
          -  Non-healing wound, ulcer, or bone fracture&#xD;
&#xD;
          -  Evidence or history of bleeding diathesis or coagulopathy disorder&#xD;
&#xD;
          -  Hemorrhage/bleeding event ≥ Grade 3&#xD;
&#xD;
          -  Thrombotic or embolic events including transient ischemic attacks within the past 6&#xD;
             months&#xD;
&#xD;
          -  Subjects with symptomatic brain metastases or Subjects with brain metastases under&#xD;
             corticosteroid treatment&#xD;
&#xD;
          -  Pregnant or breast-feeding patients&#xD;
&#xD;
          -  Patients with uncontrolled infections&#xD;
&#xD;
          -  Known HIV infection or infection with hepatitis B or C&#xD;
&#xD;
          -  Immunosuppression&#xD;
&#xD;
          -  Subjects with seizure disorder requiring medication • Subjects undergoing renal&#xD;
             dialysis&#xD;
&#xD;
          -  Substance abuse, medical, psychological or social conditions that may interfere with&#xD;
             the subject's participation in the study or evaluation of the study results&#xD;
&#xD;
          -  Any malabsorption condition&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital Ulm, Clinic for Nuclear Medicine</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Wuerttemberg</state>
        <zip>D-89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <study_first_submitted>October 23, 2012</study_first_submitted>
  <study_first_submitted_qc>November 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 29, 2012</study_first_posted>
  <last_update_submitted>May 16, 2013</last_update_submitted>
  <last_update_submitted_qc>May 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Medullary Thyroid Carcinoma</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Efficacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Neuroendocrine</mesh_term>
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

